2Maletzkii C,Emmrich J.Inflammation and immunity in the tumor environment[J].Dig Dis,2010,28(4-5):574-578.
3Diakos CI,Charles KA,Mcmillan DC,et al.Cancer-related inflammation and treatment effectiveness[J].Lancet Oncol,2014,15(11):e493-e503.
4Richards P,Riff D,Kelen R,et al.A phase 3,randomized,double-blind comparison of analgesic efficacy and tolerability of Q8003 vs oxycodone or morphine for moderate-to-severe postoperative pain following bunionectomy surgery[J].Pain Med,2013,14(8):1230-1238.
5Melson T,Boyer DL,Minkowitz HS,et al.Sufentanil sublingual tablet system vs.intravenous patient-controlled analgesia with morphine for postoperative pain control:a randomized,active-comparator trial[J].Pain Pract,2014,14(8):679-688.
6Liao SL,Chen WY,Raung SL,et al.Neuroprotection of naloxone against ischemic injury in rats:role of mu receptor antagonism[J].Neurosci Lett,2003,345(3):169-172.
7Liu R,Huang XP,Yeliseev A,et al.Novel molecular targets of dezocine and their clinical implications[J].Anesthesiology,2014,120(3):714-723.
8赵艳秋.硫酸吗啡控释片治疗癌性疼痛的临床研究.郑州大学,2014.
9Staquet M.A double-blind study of dezocine in cancer pain.J Clin Pharmacol,1979,19:392-394.
